Laser
A 2014 systematic review of case reports and case series concluded that the limited available data suggest pulsed dye laser therapy is a safe and effective treatment for molluscum contagiosum and is generally well tolerated by children. Side effects seen with pulsed dye laser therapy included mild temporary pain at the site of therapy, bruising (lasting up to 2–3 weeks), and temporary discoloration of the treated skin (as long as 1–6 months). No cases of permanent scarring have been reported. As of 2009, however, there is no evidence for genital lesions. Prognosis
Most cases of molluscum contagiosum will clear up naturally within two years (usually within nine months). So long as the skin growths are present, there is a possibility of transmitting the infection to another person. When the growths are gone, the possibility of spreading the infection is ended.Unlike herpesviruses, which can remain inactive in the body for months or years before reappearing, molluscum contagiosum does not remain in the body when the growths are gone from the skin and will not reappear on their own. Epidemiology
As of 2010, approximately 122 million people were affected worldwide by molluscum contagiosum (1.8% of the population). See also
Acrochordons (also called skin tags—similar in appearance and grow in similar areas)
Basal-cell carcinoma
Wart (caused by the human papillomavirus; also similar in appearance to molluscum)

References
External links

Molluscum—Center for Disease Control
Virus Pathogen Database and Analysis Resource (ViPR): Poxviridae
No  treatment or prevention methods are established, but patients with upper-extremity PTS may wear a compression sleeve for persistent symptoms. Epidemiology
PTS can affect 23 to 60% of patients in the two years following DVT of the leg. Of those, 10% may go on to develop severe PTS, involving venous ulcers. Society and culture
Treatment of PTS adds significantly to the cost of treating DVT. The annual health care cost of PTS in the United States has been estimated at $200 million, with costs over $3800 per patient in the first year alone, and increasing with disease severity. PTS also causes lost work productivity: people with severe PTS and venous ulcers lose up to 2 work days per year. Research directions
The field of PTS still holds many unanswered questions that are important targets for more research. Those include

Fully defining the pathophysiology of PTS, including the role of inflammation and residual thrombus after completion of an appropriate duration of anticoagulant therapy
Developing a PTS risk prediction model
Role of thrombolytic ("clot-busting") drugs in PTS prevention
Defining the true efficacy of elastic compression stockings for PTS prevention (and if effective, elucidating the minimum compression strength necessary and the optimal timing and duration of compression therapy)
Whether PTS prevention methods are necessary for patients with asymptomatic or distal DVT
Additional treatment options for PTS with demonstrated safety and efficacy (compression and pharmacologic therapies)

References


== External links ==